Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD11B1 | P28845 | 19/20 | 0.39 |
| ▸ | HSD11B2 | P80365 | 13/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.39 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | PPARA | Q07869 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2824066 | 0.87 | HSD11B1 (0.42) | HSD11B1HSD11B2 | |
| SCHEMBL2822992 | 0.85 | HSD11B1 (0.57) | HSD11B1HSD11B2 | |
| SCHEMBL2829492 | 0.83 | HSD11B1 (0.39) | HSD11B1HSD11B2MEN1CYP1A2CYP3A4 | |
| SCHEMBL2829490 | 0.83 | HSD11B1 (0.39) | HSD11B1HSD11B2MEN1CYP1A2CYP3A4 | |
| SCHEMBL2829043 | 0.83 | HSD11B1 (0.59) | HSD11B1HSD11B2 | |
| SCHEMBL2830619 | 0.83 | HSD11B1 (0.43) | HSD11B1HSD11B2 | |
| SCHEMBL2824672 | 0.82 | HSD11B1 (0.60) | HSD11B1HSD11B2 | |
| SCHEMBL2826272 | 0.82 | HSD11B1 (0.46) | HSD11B1HSD11B2 | |
| SCHEMBL2832932 | 0.81 | HSD11B1 (0.47) | HSD11B1HSD11B2 | |
| SCHEMBL2823826 | 0.80 | HSD11B1 (0.46) | HSD11B1HSD11B2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8507493-B2 | Amide and amidine derivatives and uses thereof | ABBVIE INC. (US) | 2013-08-13 | — | — | US | claimed |
| EP-2243479-A2 | Novel amide and amidine derivates and uses thereof | Abbott Laboratories (US) | 2010-10-27 | — | — | EP | claimed |
| US-20100267738-A1 | NOVEL AMIDE AND AMIDINE DERIVATIVES AND USES THEREOF | ABBOTT LABORATORIES (US) | 2010-10-21 | — | — | US | claimed |
| EP-2243479-A2 | Novel amide and amidine derivates and uses thereof | Abbott Laboratories (US) | 2010-10-27 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100267738-A1 | NOVEL AMIDE AND AMIDINE DERIVATIVES AND USES THEREOF | HSD11B2, HSD11B1, HSD17B2 | HSD11B1 2/4885HSD11B2 1/4885MEN1 1978/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.